Document:

10-K 2007 Exhibit 10.15a

                                                                                    Exhibit 10.15a

2005 Omnibus Incentive Plan

NPS Pharmaceuticals, Inc.

Effective as of May 12, 2005 and amended on December 28, 2007

Article 1. Establishment, Purpose, and Duration

1.1 Establishment. NPS Pharmaceuticals, Inc., a Delaware corporation (hereinafter referred to as the "Company"),
establishes an incentive compensation plan to be known as the NPS Pharmaceuticals, Inc. 2005 Omnibus Incentive Plan (hereinafter referred to
as the "Plan"), as set forth in this document.

This Plan permits the grant of Nonqualified Stock Options, Incentive Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted
Stock Units, Performance Shares, Performance Units, Cash-Based Awards, and Other Stock-Based Awards.

This Plan shall become effective upon stockholder approval (the "Effective Date") and shall remain in effect as provided in Section
1.3 hereof.

1.2 Purpose of this Plan. This Plan has been established by the Company to provide a means by which Employees, Directors, and
Third Party Service Providers of the Company and its Subsidiaries and Affiliates may be given the opportunity to benefit from increases in the
value of Shares through the granting of Awards under this Plan. The Company seeks to (a) retain the services of present Employees, Directors,
and Third Party Service Providers; (b) secure and retain the services of new Employees, Directors, and Third Party Service Providers; and, (c)
provide incentives for such persons to exert maximum efforts for the success of the Company and thereby promote the long-term interests of the
Company, including the growth in value of the Company's equity and enhancement of long-term stockholder return.

1.3 Duration of this Plan. Unless sooner terminated as provided herein, this Plan shall terminate ten (10) years from the Effective
Date. After this Plan is terminated, no Awards may be granted but Awards previously granted shall remain outstanding in accordance with their
applicable terms and conditions and this Plan's terms and conditions. Notwithstanding the foregoing, no Incentive Stock Options may be granted
more than ten (10) years after the earlier of (a) adoption of this Plan by the Board, or (b) the Effective Date.

Article 2. Definitions

Whenever used in this Plan, the following terms shall have the meanings set forth below, and when the meaning is intended, the initial letter
of the word shall be capitalized.

2.1 "Affiliate" shall mean any corporation or other entity (including, but not limited to, a partnership or a limited liability
company), that is affiliated with the Company through stock or

equity ownership or otherwise, and is designated as an Affiliate for purposes of this Plan by the Committee.

2.2 "Annual Award Limit" or "Annual Award Limits" have the meaning set forth in Section 4.3.

2.3 "Award" means, individually or collectively, a grant under this Plan of Nonqualified Stock Options, Incentive Stock
Options, SARs, Restricted Stock, Restricted Stock Units, Performance Shares, Performance Units, Cash-Based Awards, or Other Stock-Based
Awards, in each case subject to the terms of this Plan.

2.4 "Award Agreement" means either (i) a written agreement entered into by the Company and a Participant setting forth
the terms and provisions applicable to an Award granted under this Plan, or (ii) a written or electronic statement issued by the Company to a
Participant describing the terms and provisions of such Award, including any amendment or modification thereof. The Committee may provide for
the use of electronic, internet or other non-paper Award Agreements, and the use of electronic, internet or other non-paper means for the
acceptance thereof and actions thereunder by a Participant.

2.5 "Beneficial Owner" or "Beneficial Ownership" shall have the meaning ascribed to such term in
Rule 13d-3 of the General Rules and Regulations under the Exchange Act.

2.6 "Board" or "Board of Directors" means the Board of Directors of the Company.

2.7 "Cash-Based Award" means an Award, denominated in cash, granted to a Participant as described in Article 10.

2.8 "Code" means the U.S. Internal Revenue Code of 1986, as amended from time to time. For purposes of this Plan,
references to sections of the Code shall be deemed to include references to any applicable regulations thereunder and any successor or similar
provision.

2.9 "Committee" means the Compensation Committee of the Board or a subcommittee thereof, or any other committee
designated by the Board to administer this Plan. If the Committee does not exist or cannot function for any reason, the Board may take any action
under the Plan that would otherwise be the responsibility of the Committee.

2.10 "Company" means NPS Pharmaceuticals, Inc., a Delaware corporation, and any successor thereto as
provided in Article 19 herein.

2.11 "Covered Employee" means any salaried Employee who is or may become a "Covered Employee," as
defined in Code Section 162(m), and who is designated, either as an individual Employee or class of Employees, by the Committee within the
shorter of (i) ninety (90) days after the beginning of the Performance Period, or (ii) twenty-five percent (25%) of the Performance Period has
elapsed, as a "Covered Employee" under this Plan for such applicable Performance Period.

                                                    -2-

2.12 "Director" means any individual who is a member of the Board of Directors of the Company.

2.13 "Effective Date" has the meaning set forth in Section 1.1.

2.14 "Employee" means any person designated as an employee of the Company, its Affiliates, and/or its Subsidiaries on
the payroll records thereof. An Employee shall not include any individual during any period he or she is classified or treated by the Company,
Affiliate, and/or Subsidiary as an independent contractor, a consultant, or any employee of an employment, consulting, or temporary agency or
any other entity other than the Company, Affiliate, and/or Subsidiary, without regard to whether such individual is subsequently determined to
have been, or is subsequently retroactively reclassified as a common-law employee of the Company, Affiliate, and/or Subsidiary during such
period.

2.15 "Exchange Act" means the Securities Exchange Act of 1934, as amended from time to time, or any successor act
thereto.

2.16 "Fair Market Value" or "FMV" means a price that is based on the opening, closing, actual, high,
low, or average selling prices of a Share reported on the National Market System of the National Association of Securities Dealers, Inc.
Automated Quotation System ("Nasdaq") or other established stock exchange (or exchanges) on the applicable date, the preceding
trading day, the next succeeding trading day, or an average of trading days, as determined by the Committee in its discretion. Unless the
Committee determines otherwise, Fair Market Value shall be deemed to be equal to the closing price of a Share on the most recent date on
which Shares were publicly traded. In the event Shares are not publicly traded at the time a determination of their value is required to be made
hereunder, the determination of their Fair Market Value shall be made by the Committee in such manner as it deems appropriate. Such
definition(s) of FMV shall be specified in each Award Agreement and may differ depending on whether FMV is in reference to the grant, exercise,
vesting, settlement, or payout of an Award.

2.17 "Freestanding SAR" means an SAR that is granted independently of any Options, as described in Article 7.

2.18 "Full Value Award" means an Award other than in the form of an ISO, NQSO, or SAR, and which is settled by the
issuance of Shares.

2.19 "Grant Price" means the price established at the time of grant of a SAR pursuant to Article 7, used to determine
whether there is any payment due upon exercise of the SAR.

2.20 "Incentive Stock Option" or "ISO" means an Option to purchase Shares granted under Article 6
to an Employee and that is designated as an Incentive Stock Option and that is intended to meet the requirements of Code Section 422, or any
successor provision.

2.21 "Insider" shall mean an individual who is, on the relevant date, an officer, or Director of the Company, or a more
than ten percent (10%) Beneficial Owner of any class of the Company's equity securities that is registered pursuant to Section 12 of the Exchange Act, as

                                                    -3-

determined by the Board in accordance with Section 16 of the Exchange Act.

2.22 "Nonemployee Director" means a Director who is not an Employee.

2.23 "Nonemployee Director Award" means any NQSO, SAR, or Full Value Award granted, whether singly, in
combination, or in tandem, to a Participant who is a Nonemployee Director pursuant to such applicable terms, conditions, and limitations as the
Board or Committee may establish in accordance with this Plan.

2.24 "Nonqualified Stock Option" or "NQSO" means an Option that is not intended to meet the
requirements of Code Section 422, or that otherwise does not meet such requirements.

2.25 "Option" means an Incentive Stock Option or a Nonqualified Stock Option, as described in Article 6.

2.26 "Option Price" means the price at which a Share may be purchased by a Participant pursuant to an Option.

2.27 "Other Stock-Based Award" means an equity-based or equity-related Award not otherwise described by the terms
of this Plan, granted pursuant to Article 10.

2.28 "Participant" means any eligible individual as set forth in Article 5 to whom an Award is granted.

2.29 "Performance-Based Compensation" means compensation under an Award that is intended to satisfy the
requirements of Code Section 162(m) for certain performance-based compensation paid to Covered Employees. Notwithstanding the foregoing,
nothing in this Plan shall be construed to mean that an Award which does not satisfy the requirements for performance-based compensation
under Code Section 162(m) does not constitute performance-based compensation for other purposes, including Code Section 409A.

2.30 "Performance Measures" means measures as described in Article 11 on which the performance goals are based
and which are approved by the Company's stockholders pursuant to this Plan in order to qualify Awards as Performance-Based
Compensation.

2.31 "Performance Period" means the period of time during which the performance goals must be met in order to
determine the degree of payout and/or vesting with respect to an Award.

2.32 "Performance Share" means an Award under Article 9 herein and subject to the terms of this Plan, denominated in
Shares, the value of which at the time it is payable is determined as a function of the extent to which corresponding performance criteria have
been achieved.

2.33 "Performance Unit" means an Award under Article 9 herein and subject to the terms of this Plan, denominated in
units, the value of which at the time it is payable is determined as a function of the extent to which corresponding performance criteria have been
achieved.

                                                    -4-

2.34 "Period of Restriction" means the period when Restricted Stock or Restricted Stock Units are subject to a
substantial risk of forfeiture (based on the passage of time, the achievement of performance goals, or upon the occurrence of other events as
determined by the Committee, in its discretion), as provided in Article 8.

2.35 "Person" shall have the meaning ascribed to such term in Section 3(a)(9) of the Exchange Act and used in Sections
13(d) and 14(d) thereof, including a "group" as defined in Section 13(d) thereof.

2.36 "Plan" means the NPS Pharmaceuticals, Inc. 2005 Omnibus Incentive Plan.

2.37 "Plan Year" means the Company's fiscal year.

2.38 "Restricted Stock" means an Award granted to a Participant pursuant to Article 8.

2.39 "Restricted Stock Unit" means an Award granted to a Participant pursuant to Article 8, except no Shares are
actually awarded to the Participant on the date of grant.

2.40 "Share" means a share of common stock of the Company, par value of $.001 per share.

2.41 "Stock Appreciation Right" or "SAR" means an Award, designated as a SAR, pursuant to the
terms of Article 7 herein.

2.42 "Subsidiary" means any corporation or other entity, whether domestic or foreign, in which the Company has or
obtains, directly or indirectly, a proprietary interest of more than fifty percent (50%) by reason of stock ownership or otherwise.

2.43 "Tandem SAR" means an SAR that is granted in connection with a related Option pursuant to Article 7 herein, the
exercise of which shall require forfeiture of the right to purchase a Share under the related Option (and when a Share is purchased under the
Option, the Tandem SAR shall similarly be canceled).

2.44 "Third Party Service Provider" means any consultant, agent, advisor, or independent contractor who renders
services to the Company, a Subsidiary, or an Affiliate that (a) are not in connection with the offer and sale of the Company's securities in a capital
raising transaction, and (b) do not directly or indirectly promote or maintain a market for the Company's securities.

Article 3. Administration

3.1 General. The Plan shall be administered by or under the direction of the Board unless and until the Board delegates
administration to a Committee. The Board may employ attorneys, consultants, accountants, agents, and other individuals, any of whom may be
an Employee, and the Board, the Company, and its officers and Directors shall be entitled to rely upon the advice,

                                                    -5-

opinions, or valuations of any
such individuals. All actions taken and all interpretations and determinations made by the Board shall be final and binding upon the Participants,
the Company, and all other interested individuals.

3.2 Authority of the Board. The Board shall have full and exclusive discretionary power to interpret the terms and the intent of this
Plan and any Award Agreement or other agreement or document ancillary to or in connection with this Plan, to determine eligibility for Awards
and to adopt such rules, regulations, forms, instruments, and guidelines for administering this Plan as the Board may deem necessary or proper.
Such authority shall include, but not be limited to, selecting Award recipients, establishing all Award terms and conditions, including the terms and
conditions set forth in Award Agreements, granting Awards as an alternative to or as the form of payment for grants or rights earned or due under
compensation plans or arrangements of the Company, construing any ambiguous provision of the Plan or any Award Agreement, and, subject to
Article 16, adopting modifications and amendments to this Plan or any Award Agreement, including without limitation, any that are necessary to
comply with the laws of the countries and other jurisdictions in which the Company, its Affiliates, and/or its Subsidiaries operate.

3.3 Delegation.

(a) The Board may delegate administration of the Plan to a Board committee composed of not fewer than two members (the
"Committee"). All members of the Committee shall be Nonemployee Directors, to the extent necessary to comply with the applicable
provisions of Rule 16b-3, Section 162(m) and the listing requirements of the Nasdaq Stock Market. If administration is delegated to a Committee,
the Committee shall have, in connection with the administration of the Plan, the powers theretofore possessed by the Board (and references in
this Plan to the Board shall in such event, be to the Committee), subject, however, to such resolutions, not inconsistent with the provisions of the
Plan, as may be adopted from time to time by the Board. The Board may abolish the Committee at any time and revest in the Board the
administration of the Plan.

(b) The Board may delegate to one or more of its members or to one or more officers of the Company, and/or its Subsidiaries and Affiliates or
to one or more agents or advisors such administrative duties or powers as it may deem advisable, and the Board or any individuals to whom it
has delegated duties or powers as aforesaid may employ one or more individuals to render advice with respect to any responsibility the Board or
such individuals may have under this Plan. The Board may, by resolution, authorize one or more officers of the Company to do one or both of the
following on the same basis as can the Board: (a) designate Employees to be recipients of Awards; and (b) determine the size of any such
Awards; provided, however, (i) the Board shall not delegate such responsibilities to any such officer for Awards granted to an Employee who is
considered an Insider; (ii) the resolution providing such authorization sets forth the total number of Awards such officer(s) may grant; and (iii) the
officer(s) shall report periodically to the Board regarding the nature and scope of the Awards granted pursuant to the authority delegated.

Article 4. Shares Subject to this Plan and Maximum Awards

                                                    -6-

4.1 Number of Shares Available for Awards.

(a) Subject to adjustment as provided in Section 4.4 herein, the maximum number of Shares available for grant to Participants under this
Plan shall be two million seven hundred thousand (2,700,000) Shares (the "Share Authorization").

(b) The maximum number of Shares of the Share Authorization that may be issued pursuant to ISOs under this Plan shall be two million
seven hundred thousand (2,700,000) Shares.

4.2 Share Usage. Shares covered by an Award shall only be counted as used to the extent they are actually issued. Any Shares
related to Awards which terminate by expiration, forfeiture, cancellation, or otherwise without the issuance of such Shares, are settled in cash in
lieu of Shares, or are exchanged with the Board's permission, prior to the issuance of Shares, for Awards not involving Shares, shall be available
again for grant under this Plan. Moreover, if the Option Price of any Option granted under this Plan or the tax withholding requirements with
respect to any Award granted under this Plan are satisfied by tendering Shares to the Company (by either actual delivery or by attestation), or if
an SAR is exercised, only the number of Shares issued, net of the Shares tendered, if any, will be deemed delivered for purposes of determining
the maximum number of Shares available for delivery under this Plan. The Shares available for issuance under this Plan may be authorized and
unissued Shares or treasury Shares.

4.3 Annual Award Limits. Unless and until the Board determines that an Award to a Covered Employee shall not be designed to
qualify as Performance-Based Compensation, the following limits (each an "Annual Award Limit" and, collectively, "Annual
Award Limits") shall apply to grants of such Awards under this Plan:

(a) Options: The maximum aggregate number of Shares subject to Options granted in any one Plan Year to any one Participant
shall be one hundred fifty thousand (150,000) plus the amount of the Participant's unused applicable Annual Award Limit for Options as of the
close of the previous Plan Year.

(b) SARs: The maximum number of Shares subject to Stock Appreciation Rights granted in any one Plan Year to any one
Participant shall one hundred fifty thousand (150,000) plus the amount of the Participant's unused applicable Annual Award Limit for SARs as of
the close of the previous Plan Year.

(c) Restricted Stock or Restricted Stock Units: The maximum aggregate grant with respect to Awards of Restricted Stock or
Restricted Stock Units in any one Plan Year to any one Participant shall be eighty thousand (80,000) plus the amount of the Participant's unused
applicable Annual Award Limit for Restricted Stock or Restricted Stock Units as of the close of the previous Plan Year.

(d) Performance Units or Performance Shares: The maximum aggregate Award of Performance Units or Performance Shares that a
Participant may receive in any one Plan Year

                                                    -7-

shall be eighty thousand (80,000) Shares, or equal to the value of eighty thousand (80,000) Shares
determined as of the date of vesting or payout, as applicable plus the amount of the Participant's unused applicable Annual Award Limit for
Performance Units or Performance Shares as of the close of the previous Plan Year.

(e) Cash-Based Awards: The maximum aggregate amount awarded or credited with respect to Cash-Based Awards to any one
Participant in any one Plan Year may not exceed the value of one million dollars ($1,000,000), plus the amount of the Participant's unused
applicable Annual Award Limit as of the close of the previous Plan Year.

(f) Other Stock-Based Awards. The maximum aggregate grant with respect to Other Stock-Based Awards pursuant to Section 10.2
in any one Plan Year to any one Participant shall be eighty thousand (80,000) plus the amount of the Participant's unused applicable Annual
Award Limit for Other Stock-Based Awards as of the close of the previous Plan Year.

4.4 Adjustments in Authorized Shares. In the event of any corporate event or transaction (including, but not limited to, a change in
the Shares of the Company or the capitalization of the Company) such as a merger, consolidation, reorganization, recapitalization, separation,
partial or complete liquidation, stock dividend, stock split, reverse stock split, split up, spin-off, or other distribution of stock or property of the
Company, combination of Shares, exchange of Shares, dividend in kind, or other like change in capital structure, number of outstanding Shares
or distribution (other than normal cash dividends) to shareholders of the Company, or any similar corporate event or transaction, the Board, in its
sole discretion, in order to prevent dilution or enlargement of Participants' rights under this Plan, shall substitute or adjust, as applicable, the
number and kind of Shares that may be issued under this Plan or under particular forms of Awards, the number and kind of Shares subject to
outstanding Awards, the Option Price or Grant Price applicable to outstanding Awards, the Annual Award Limits, and other value determinations
applicable to outstanding Awards. The Board, in its sole discretion, may also make appropriate adjustments in the terms of any Awards under this
Plan to reflect or related to such changes or distributions and to modify any other terms of outstanding Awards. The determination of the Board as
to the foregoing adjustments, if any, shall be conclusive and binding on Participants under this Plan.

Subject to the provisions of Article 16 and notwithstanding anything else herein to the contrary, without affecting the number of Shares
reserved or available hereunder, the Board may authorize the issuance or assumption of benefits under this Plan in connection with any merger,
consolidation, acquisition of property or stock, or reorganization upon such terms and conditions as it may deem appropriate (including, but not
limited to, a conversion of equity awards into Awards under this Plan in a manner consistent with paragraph 53 of FASB Interpretation No. 44),
subject to compliance with the rules under Code Sections 422 and 424, as and where applicable.

Article 5. Eligibility and Participation

5.1 Eligibility. Individuals eligible to participate in this Plan include all Employees, Directors, and Third Party Service Providers.

                                                    -8-

5.2 Actual Participation. Subject to the provisions of this Plan, the Board may, from time to time, select from all eligible individuals,
those individuals to whom Awards shall be granted and shall determine, in its sole discretion, the nature of, any and all terms permissible by law,
and the amount of each Award.

Article 6. Stock Options

6.1 Grant of Options. Subject to the terms and provisions of this Plan, Options may be granted to Participants in such number, and
upon such terms, and at any time and from time to time as shall be determined by the Board, in its sole discretion; provided that ISOs may be
granted only to eligible Employees of the Company or of any parent or subsidiary corporation (as permitted under Code Sections 422 and 424).
However, an Employee who is employed by an Affiliate and/or Subsidiary and is subject to Code Section 409A, may only be granted Options to
the extent the Affiliate and/or Subsidiary is part of the Company's consolidated group for United States federal tax purposes.

6.2 Award Agreement. Each Option grant shall be evidenced by an Award Agreement that shall specify the Option Price, the
maximum duration of the Option, the number of Shares to which the Option pertains, the conditions upon which an Option shall become vested
and exercisable, and such other provisions as the Board shall determine which are not inconsistent with the terms of this Plan. The Award
Agreement also shall specify whether the Option is intended to be an ISO or a NQSO.

6.3 Option Price. The Option Price for each grant of an Option under this Plan shall be determined by the Board in its sole discretion
and shall be specified in the Award Agreement; provided, however, the Option Price on the date of grant must be at least equal to one hundred
percent (100%) of the FMV of the Shares as determined on the date of grant.

6.4 Term of Options. Each Option granted to a Participant shall expire at such time as the Board shall determine at the time of grant;
provided, however, no Option shall be exercisable later than the tenth (10 th ) anniversary date of its grant. Notwithstanding the
foregoing, for Nonqualified Stock Options granted to Participants outside the United States, the Board has the authority to grant Nonqualified
Stock Options that have a term greater than ten (10) years.

6.5 Exercise of Options. Options granted under this Article 6 shall be exercisable at such times and be subject to such restrictions
and conditions as the Board shall in each instance approve, which terms and restrictions need not be the same for each grant or for each
Participant.

6.6 Payment. Options granted under this Article 6 shall be exercised by the delivery of a notice of exercise to the Company or an
agent designated by the Company in a form specified or accepted by the Board, or by complying with any alternative procedures which may be
authorized by the Board, setting forth the number of Shares with respect to which the Option is to be exercised, accompanied by full payment for
the Shares.

A condition of the issuance of the Shares as to which an Option shall be exercised shall be

                                                    -9-

the payment of the Option Price. The Option Price
of any Option shall be payable to the Company in full either: (a) in cash or its equivalent; (b) by tendering (either by actual delivery or attestation)
previously acquired Shares having an aggregate Fair Market Value at the time of exercise equal to the Option Price (provided that except as
otherwise determined by the Board, the Shares that are tendered must have been held by the Participant for at least six (6) months (or such other
period, if any, as the Board may permit) prior to their tender to satisfy the Option Price if acquired under this Plan or any other compensation plan
maintained by the Company or have been purchased on the open market); (c) pursuant to a broker-assisted exercise same-day sales program;
(d) by a combination of (a) (b), and (c); or (e) any other method approved or accepted by the Board in its sole discretion.

Subject to any governing rules or regulations, as soon as practicable after receipt of written notification of exercise and full payment
(including satisfaction of any applicable tax withholding), the Company shall deliver to the Participant evidence of book entry Shares, or upon the
Participant's request, Share certificates in an appropriate amount based upon the number of Shares purchased under the Option(s).

Unless otherwise determined by the Board, all payments under all of the methods indicated above shall be paid in United States dollars.

6.7 Restrictions on Share Transferability. The Board may impose such restrictions on any Shares acquired pursuant to the exercise
of an Option granted under this Article 6 as it may deem advisable, including, without limitation, minimum holding period requirements,
restrictions under applicable federal securities laws, under the requirements of any stock exchange or market upon which such Shares are then
listed and/or traded, or under any blue sky or state securities laws applicable to such Shares.

6.8 Termination of Employment. Each Participant's Award Agreement shall set forth the extent to which the Participant shall have
the right to exercise the Option following termination of the Participant's employment or provision of services to the Company, its Affiliates, and/or
its Subsidiaries, as the case may be. Such provisions shall be determined in the sole discretion of the Board, shall be included in the Award
Agreement entered into with each Participant, need not be uniform among all Options issued pursuant to this Article 6, and may reflect
distinctions based on the reasons for termination.

6.9 Notification of Disqualifying Disposition. If any Participant shall make any disposition of Shares issued pursuant to the exercise
of an ISO under the circumstances described in Code Section 421(b) (relating to certain disqualifying dispositions), such Participant shall notify
the Company of such disposition prior to the end of the calendar year in which such disposition occurred.

6.10 Retirement of Participant. Notwithstanding any contrary provision in this Plan, in the event a Participant's employment as an
Employee, or service as a Director or Third Party Service Provider terminates due to a Participant's Retirement, the Participant shall vest in that
number of Shares subject to the Option that would have vested had the Participant remained an Employee, Director, or Third Party Service
Provider for an additional two (2) years from the date of

                                                    -10-

Retirement. In addition, the Option shall remain exercisable until the expiration of its term.
For purposes of this paragraph, "Retirement" shall mean the termination of service of a Participant with the Company, a Subsidiary, or
an Affiliate on or after the date on which the Participant's number of completed years of service with the Company, a Subsidiary, or Affiliate and
age equal or exceed seventy (70) (including termination due to death or Disability after such time).

Article 7. Stock Appreciation Rights

7.1 Grant of SARs. Subject to the terms and conditions of this Plan, SARs may be granted to Participants at any time and from time
to time as shall be determined by the Board. The Board may grant Freestanding SARs, Tandem SARs, or any combination of these forms of
SARs. However, an Employee who is employed by an Affiliate and/or Subsidiary and is subject to Code Section 409A, may only be granted
SARs to the extent the Affiliate and/or Subsidiary is part of the Company's consolidated group for United States federal tax purposes.

Subject to the terms and conditions of this Plan, the Board shall have complete discretion in determining the number of SARs granted to each
Participant and, consistent with the provisions of this Plan, in determining the terms and conditions pertaining to such SARs.

The Grant Price for each grant of a Freestanding SAR shall be determined by the Board and shall be specified in the Award Agreement;
provided, however, the Grant Price on the date of grant must be at least equal to one hundred percent (100%) of the FMV of the Shares as
determined on the date of grant. The Grant Price of Tandem SARs shall be equal to the Option Price of the related Option.

7.2 SAR Agreement. Each SAR Award shall be evidenced by an Award Agreement that shall specify the Grant Price, the term of the
SAR, and such other provisions as the Board shall determine.

7.3 Term of SAR. The term of an SAR granted under this Plan shall be determined by the Board, in its sole discretion, and except as
determined otherwise by the Board and specified in the SAR Award Agreement, no SAR shall be exercisable later than the tenth (10
th ) anniversary date of its grant. Notwithstanding the foregoing, for SARs granted to Participants outside the United States, the Board
has the authority to grant SARs that have a term greater than ten (10) years.

7.4 Exercise of Freestanding SARs. Freestanding SARs may be exercised upon whatever terms and conditions the Board, in its
sole discretion, imposes.

7.5. Exercise of Tandem SARs. Tandem SARs may be exercised for all or part of the Shares subject to the related Option upon the
surrender of the right to exercise the equivalent portion of the related Option. A Tandem SAR may be exercised only with respect to the Shares
for which its related Option is then exercisable.

Notwithstanding any other provision of this Plan to the contrary, with respect to a Tandem SAR granted in connection with an ISO: (a) the
Tandem SAR will expire no later than the

                                                    -11-

expiration of the underlying ISO; (b) the value of the payout with respect to the Tandem SAR may be for
no more than one hundred percent (100%) of the excess of the Fair Market Value of the Shares subject to the underlying ISO at the time the
Tandem SAR is exercised over the Option Price of the underlying ISO; and (c) the Tandem SAR may be exercised only when the Fair Market
Value of the Shares subject to the ISO exceeds the Option Price of the ISO.

7.6 Settlement of SAR Amount. Upon the exercise of an SAR, a Participant shall be entitled to receive payment from the Company
in an amount determined by multiplying:

(a) The excess of the Fair Market Value of a Share on the date of exercise over the Grant Price; by

(b) The number of Shares with respect to which the SAR is exercised.

At the discretion of the Board, the payment upon SAR exercise may be in cash, Shares, or any combination thereof, or in any other manner
approved by the Board in its sole discretion. The Board's determination regarding the form of SAR payout shall be set forth in the Award
Agreement pertaining to the grant of the SAR.

7.7 Termination of Employment. Each Award Agreement shall set forth the extent to which the Participant shall have the right to
exercise the SAR following termination of the Participant's employment with or provision of services to the Company, its Affiliates, and/or its
Subsidiaries, as the case may be. Such provisions shall be determined in the sole discretion of the Board, shall be included in the Award
Agreement entered into with Participants, need not be uniform among all SARs issued pursuant to this Plan, and may reflect distinctions based
on the reasons for termination.

7.8 Other Restrictions. The Board shall impose such other conditions and/or restrictions on any Shares received upon exercise of a
SAR granted pursuant to this Plan as it may deem advisable or desirable. These restrictions may include, but shall not be limited to, a
requirement that the Participant hold the Shares received upon exercise of a SAR for a specified period of time.

Article 8. Restricted Stock and Restricted Stock Units

8.1 Grant of Restricted Stock or Restricted Stock Units. Subject to the terms and provisions of this Plan, the Board, at any time and
from time to time, may grant Shares of Restricted Stock and/or Restricted Stock Units to Participants in such amounts as the Board shall
determine. Restricted Stock Units shall be similar to Restricted Stock except that no Shares are actually awarded to the Participant on the date of
grant.

8.2 Restricted Stock or Restricted Stock Unit Agreement. Each Restricted Stock and/or Restricted Stock Unit grant shall be
evidenced by an Award Agreement that shall specify the Period(s) of Restriction, if any, the number of Shares of Restricted Stock or the number
of Restricted Stock Units granted, and such other provisions as the Board shall determine.

                                                    -12-

8.3 Other Restrictions. The Board shall impose such other conditions and/or restrictions, if any, on any Shares of Restricted Stock or
Restricted Stock Units granted pursuant to this Plan as it may deem advisable including, without limitation, a requirement that Participants pay a
stipulated purchase price for each Share of Restricted Stock or each Restricted Stock Unit, restrictions based upon the achievement of specific
performance goals, time-based restrictions on vesting following the attainment of the performance goals, time-based restrictions, and/or
restrictions under applicable laws or under the requirements of any stock exchange or market upon which such Shares are listed or traded, or
holding requirements or sale restrictions placed on the Shares by the Company upon vesting of such Restricted Stock or Restricted Stock
Units.

To the extent deemed appropriate by the Board, the Company may retain the certificates representing Shares of Restricted Stock in the
Company's possession until such time as all conditions and/or restrictions applicable to such Shares have been satisfied or lapse.

Except as otherwise provided in this Article 8, Shares of Restricted Stock covered by each Restricted Stock Award shall become freely
transferable by the Participant after all conditions and restrictions applicable to such Shares have been satisfied or lapse (including satisfaction of
any applicable tax withholding obligations), and Restricted Stock Units shall be paid in cash, Shares, or a combination of cash and Shares as the
Board, in its sole discretion shall determine.

8.4 Certificate Legend. In addition to any legends placed on certificates pursuant to Section 8.3, each certificate representing
Shares of Restricted Stock granted pursuant to this Plan may bear a legend such as the following or as otherwise determined by the Board in its
sole discretion:

THE SALE OR TRANSFER OF SHARES OF STOCK REPRESENTED BY THIS CERTIFICATE, WHETHER VOLUNTARY,
INVOLUNTARY, OR BY OPERATION OF LAW, IS SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER AS SET FORTH IN THE NPS
PHARMACEUTICALS, INC. 2005 OMNIBUS INCENTIVE PLAN, AND IN THE ASSOCIATED AWARD AGREEMENT. A COPY OF THIS PLAN
AND SUCH AWARD AGREEMENT MAY BE OBTAINED FROM NPS PHARMACEUTICALS, INC.

8.5 Voting Rights. Unless otherwise determined by the Board and set forth in a Participant's Award Agreement, to the extent
permitted or required by law, as determined by the Board, Participants holding Shares of Restricted Stock granted hereunder may be granted the
right to exercise full voting rights with respect to those Shares during the Period of Restriction. A Participant shall have no voting rights with
respect to any Restricted Stock Units granted hereunder.

8.6 Termination of Employment. Each Award Agreement shall set forth the extent to which the Participant shall have the right to
retain Restricted Stock and/or Restricted Stock Units following termination of the Participant's employment with or provision of services to the
Company, its Affiliates, and/or its Subsidiaries, as the case may be. Such provisions shall be determined in the sole discretion of the Board, shall
be included in the Award Agreement entered into with each Participant, need not be uniform among all Shares of Restricted Stock or

                                                    -13-

Restricted Stock Units issued pursuant to this Plan, and may reflect distinctions based on the reasons for termination.

8.7 Section 83(b) Election. The Board may provide in an Award Agreement that the Award of Restricted Stock is conditioned upon
the Participant making or refraining from making an election with respect to the Award under Code Section 83(b). If a Participant makes an
election pursuant to Code Section 83(b) concerning a Restricted Stock Award, the Participant shall be required to file promptly a copy of such
election with the Company.

Article 9. Performance Units/Performance Shares

9.1 Grant of Performance Units/Performance Shares. Subject to the terms and provisions of this Plan, the Board, at any time and
from time to time, may grant Performance Units and/or Performance Shares to Participants in such amounts and upon such terms as the Board
shall determine.

9.2 Value of Performance Units/Performance Shares. Each Performance Unit shall have an initial value that is established by the
Board at the time of grant. Each Performance Share shall have an initial value equal to the Fair Market Value of a Share on the date of grant. The
Board shall set performance goals in its discretion which, depending on the extent to which they are met, will determine the value and/or number
of Performance Units/Performance Shares that will be paid out to the Participant.

9.3 Earning of Performance Units/Performance Shares. Subject to the terms of this Plan, after the applicable Performance Period
has ended, the holder of Performance Units/Performance Shares shall be entitled to receive payout on the value and number of Performance
Units/Performance Shares earned by the Participant over the Performance Period, to be determined as a function of the extent to which the
corresponding performance goals have been achieved.

9.4 Form and Timing of Payment of Performance Units/Performance Shares. Payment of earned Performance Units/Performance
Shares shall be as determined by the Board and as evidenced in the Award Agreement. Subject to the terms of this Plan, the Board, in its sole
discretion, may pay earned Performance Units/Performance Shares in the form of cash or in Shares (or in a combination thereof) equal to the
value of the earned Performance Units/Performance Shares at the close of the applicable Performance Period, or as soon as practicable after the
end of the Performance Period. Any Shares may be granted subject to any restrictions deemed appropriate by the Board. The determination of
the Board with respect to the form of payout of such Awards shall be set forth in the Award Agreement pertaining to the grant of the Award.

9.5 Termination of Employment. Each Award Agreement shall set forth the extent to which the Participant shall have the right to
retain Performance Units and/or Performance Shares following termination of the Participant's employment with or provision of services to the
Company, its Affiliates, and/or its Subsidiaries, as the case may be. Such provisions shall be determined in the sole discretion of the Board, shall
be included in the Award Agreement entered

                                                    -14-

into with each Participant, need not be uniform among all Awards of Performance Units or
Performance Shares issued pursuant to this Plan, and may reflect distinctions based on the reasons for termination.

Article 10. Cash-Based Awards and Other Stock-Based Awards

10.1 Grant of Cash-Based Awards. Subject to the terms and provisions of the Plan, the Board, at any time and from time to time,
may grant Cash-Based Awards to Participants in such amounts and upon such terms as the Board may determine.

10.2 Other Stock-Based Awards. The Board may grant other types of equity-based or equity-related Awards not otherwise described
by the terms of this Plan (including the grant or offer for sale of unrestricted Shares) in such amounts and subject to such terms and conditions,
as the Board shall determine. Such Awards may involve the transfer of actual Shares to Participants, or payment in cash or otherwise of amounts
based on the value of Shares and may include, without limitation, Awards designed to comply with or take advantage of the applicable local laws
of jurisdictions other than the United States.

10.3 Value of Cash-Based and Other Stock-Based Awards. Each Cash-Based Award shall specify a payment amount or payment
range as determined by the Board. Each Other Stock-Based Award shall be expressed in terms of Shares or units based on Shares, as
determined by the Board. The Board may establish performance goals in its discretion. If the Board exercises its discretion to establish
performance goals, the number and/or value of Cash-Based Awards or Other Stock-Based Awards that will be paid out to the Participant will
depend on the extent to which the performance goals are met.

10.4 Payment of Cash-Based Awards and Other Stock-Based Awards. Payment, if any, with respect to a Cash-Based Award or an
Other Stock-Based Award shall be made in accordance with the terms of the Award, in cash or Shares as the Board determines.

10.5 Termination of Employment. The Board shall determine the extent to which the Participant shall have the right to receive Cash-
Based Awards or Other Stock-Based Awards following termination of the Participant's employment with or provision of services to the Company,
its Affiliates, and/or its Subsidiaries, as the case may be. Such provisions shall be determined in the sole discretion of the Board, such provisions
may be included in an agreement entered into with each Participant, but need not be uniform among all Awards of Cash-Based Awards or Other
Stock-Based Awards issued pursuant to the Plan, and may reflect distinctions based on the reasons for termination.

Article 11. Transferability of Awards

11.1 Transferability. Except as provided in Section 11.2 below, during a Participant's lifetime, his or her Awards shall be exercisable
only by the Participant. Awards shall not be transferable other than by will or the laws of descent and distribution; no Awards shall be subject, in
whole or in part, to attachment, execution, or levy of any kind; and any purported transfer in violation hereof shall be null and void. The Board
may establish such procedures as it

                                                    -15-

deems appropriate for a Participant to designate a beneficiary to whom any amounts payable or Shares
deliverable in the event of, or following, the Participant's death, may be provided.

11.2 Board Action. The Board may, in its discretion, determine that notwithstanding Section 11.1, any or all Awards (other than
ISOs) shall be transferable to and exercisable by such transferees, and subject to such terms and conditions, as the Board may deem
appropriate; provided, however, no Award may be transferred for value (as defined in the General Instructions to Form S-8 under the Securities
Act of 1933, as amended).

11.3 Domestic Relations Orders. Without limiting the generality of Section 11.1, and notwithstanding Section 11.2, no domestic
relations order purporting to authorize a transfer of an Award shall be recognized as valid.

Article 12. Performance Measures

12.1 Performance Measures. The performance goals upon which the payment or vesting of an Award to a Covered Employee that is
intended to qualify as Performance-Based Compensation shall be limited to the following Performance Measures:

(a) Net earnings or net income (before or after taxes);

(b) Earnings per share;

(c) Net sales or revenue growth;

(d) Net operating profit;

(e) Return measures (including, but not limited to, return on assets, capital, invested capital, equity, sales, or revenue);

(f) Cash flow (including, but not limited to, operating cash flow, free cash flow, cash flow return on equity, and cash flow return on
investment);

(g) Earnings before or after taxes, interest, depreciation, and/or amortization;

(h) Gross or operating margins;

(i) Productivity ratios;

(j) Share price (including, but not limited to, growth measures and total shareholder return);

(k) Expense targets;

(l) Margins;

(m) Operating efficiency;

                                                    -16-

(n) Market share;

(o) Customer satisfaction;

(p) Working capital targets;

(q) Economic value added or EVA® (net operating profit after tax minus the sum of capital multiplied by the cost of
capital); and

(r) Product development.

Any Performance Measure(s) may be used to measure the performance of the Company, Subsidiary, and/or Affiliate as a whole or any
business unit of the Company, Subsidiary, and/or Affiliate or any combination thereof, as the Board may deem appropriate, or any of the above
Performance Measures as compared to the performance of a group of comparator companies, or published or special index that the Board, in its
sole discretion, deems appropriate, or the Company may select Performance Measure (j) above as compared to various stock market indices.
The Board also has the authority to provide for accelerated vesting of any Award based on the achievement of performance goals pursuant to the
Performance Measures specified in this Article 12.

12.2 Evaluation of Performance. The Board may provide in any such Award that any evaluation of performance may include or
exclude any of the following events that occurs during a Performance Period: (a) asset write-downs, (b) litigation or claim judgments or
settlements, (c) the effect of changes in tax laws, accounting principles, or other laws or provisions affecting reported results, (d) any
reorganization and restructuring programs, (e) extraordinary nonrecurring items as described in Accounting Principles Board Opinion No. 30
and/or in management's discussion and analysis of financial condition and results of operations appearing in the Company's annual report to
shareholders for the applicable year, (f) acquisitions or divestitures, and (g) foreign exchange gains and losses. To the extent such inclusions or
exclusions affect Awards to Covered Employees, they shall be prescribed in a form that meets the requirements of Code Section 162(m) for
deductibility.

12.3 Adjustment of Performance-Based Compensation. Awards that are intended to qualify as Performance-Based Compensation
may not be adjusted upward. The Board shall retain the discretion to adjust such Awards downward, either on a formula or discretionary basis or
any combination, as the Board determines.

12.4 Board Discretion. In the event that applicable tax and/or securities laws change to permit Board discretion to alter the governing
Performance Measures without obtaining shareholder approval of such changes, the Board shall have sole discretion to make such changes
without obtaining shareholder approval. In addition, in the event that the Board determines that it is advisable to grant Awards that shall not
qualify as Performance-Based Compensation, the Board may make such grants without satisfying the requirements of Code Section 162(m) and
base vesting on Performance Measures other than those set forth in Section 12.1.

                                                    -17-

Article 13. Dividend Equivalents

Any Participant selected by the Board may be granted dividend equivalents based on the dividends declared on Shares that are subject to
any Award, to be credited as of dividend payment dates, during the period between the date the Award is granted and the date the Award is
exercised, vests or expires, as determined by the Board. Such dividend equivalents shall be converted to cash or additional Shares by such
formula and at such time and subject to such limitations as may be determined by the Board.

Article 14. Beneficiary Designation

Each Participant under this Plan may, from time to time, name any beneficiary or beneficiaries (who may be named contingently or
successively) to whom any benefit under this Plan is to be paid in case of his death before he receives any or all of such benefit. Each such
designation shall revoke all prior designations by the same Participant, shall be in a form prescribed by the Board, and will be effective only when
filed by the Participant in writing with the Company during the Participant's lifetime. In the absence of any such beneficiary designation, benefits
remaining unpaid or rights remaining unexercised at the Participant's death shall be paid or exercised by the Participant's executor, administrator,
or legal representative.

Article 15. Rights of Participants

15.1 Employment. Nothing in this Plan or an Award Agreement shall interfere with or limit in any way the right of the Company, its
Affiliates, and/or its Subsidiaries, to terminate any Participant's employment or service on the Board or to the Company at any time or for any
reason not prohibited by law, nor confer upon any Participant any right to continue his employment or service as a Director or Third Party Service
Provider for any specified period of time.

Neither an Award nor any benefits arising under this Plan shall constitute an employment contract with the Company, its Affiliates, and/or its
Subsidiaries and, accordingly, subject to Articles 3 and 16, this Plan and the benefits hereunder may be terminated at any time in the sole and
exclusive discretion of the Board without giving rise to any liability on the part of the Company, its Affiliates, and/or its Subsidiaries.

15.2 Participation. No individual shall have the right to be selected to receive an Award under this Plan, or, having been so selected,
to be selected to receive a future Award.

15.3 Rights as a Stockholder. Except as otherwise provided herein, a Participant shall have none of the rights of a stockholder with
respect to Shares covered by any Award until the Participant becomes the record holder of such Shares.

Article 16. Amendment, Modification, Suspension, and Termination

16.1 Amendment, Modification, Suspension, and Termination. Subject to Section 16.3,

                                                    -18-

the Board may, at any time and from time to
time, alter, amend, modify, suspend, or terminate this Plan and any Award Agreement in whole or in part; provided, however, that, without the
prior approval of the Company's stockholders and except as provided in Section 4.4, Options or SARs issued under this Plan will not be repriced,
replaced, or regranted through cancellation, or by lowering the Option Price of a previously granted Option or the Grant Price of a previously
granted SAR, and no material amendment of this Plan shall be made without stockholder approval if shareholder approval is required by law,
regulation, or stock exchange rule.

16.2 Adjustment of Awards Upon the Occurrence of Certain Unusual or Nonrecurring Events. The Board may make adjustments in
the terms and conditions of, and the criteria included in, Awards in recognition of unusual or nonrecurring events (including, without limitation, the
events described in Section 4.4 hereof) affecting the Company or the financial statements of the Company or of changes in applicable laws,
regulations, or accounting principles, whenever the Board determines that such adjustments are appropriate in order to prevent unintended
dilution or enlargement of the benefits or potential benefits intended to be made available under this Plan. The determination of the Board as to
the foregoing adjustments, if any, shall be conclusive and binding on Participants under this Plan.

16.3 Awards Previously Granted. Notwithstanding any other provision of this Plan to the contrary (other than Section 16.4), no
termination, amendment, suspension, or modification of this Plan or an Award Agreement shall adversely affect in any material way any Award
previously granted under this Plan, without the written consent of the Participant holding such Award.

16.4 Amendment to Conform to Law. Notwithstanding any other provision of this Plan to the contrary, the Board of Directors may
amend the Plan or an Award Agreement, to take effect retroactively or otherwise, as deemed necessary or advisable for the purpose of
conforming the Plan or an Award Agreement to any present or future law relating to plans of this or similar nature (including, but not limited to,
Code Section 409A), and to the administrative regulations and rulings promulgated thereunder.

Article 17. Withholding

17.1 Withholding Generally. The Company shall have the power and the right to deduct or withhold, or require a Participant to remit
to the Company, the minimum statutory amount to satisfy federal, state, and local taxes, domestic or foreign, required by law or regulation to be
withheld with respect to any taxable event arising as a result of this Plan.

17.2  Stock Withholding.  When, under applicable tax laws, a Participant incurs tax liability in
connection with the vesting of any Award that is subject to tax withholding and the Participant is obligated to pay the Company the amount
required to be withheld, the Board shall, subject to compliance with all applicable laws and regulations, allow the Participant to satisfy the
minimum withholding tax obligation by electing to have the Company withhold from the Shares to be issued upon vesting of the Award that
number of Shares having a Fair Market Value equal to the minimum amount required to be withheld, determined on the date that the amount of
tax to be withheld is to be determined. All elections by a Participant to have Shares withheld for this

                                                    -19-

purpose will be made in accordance with the requirements established by the Board and be in writing in a form acceptable to the Board. 

Article 18. Corporate Transactions

In the event of (a) a merger or consolidation in which the Company is not the surviving corporation; (b) a reverse merger in which the
Company is the surviving corporation but the shares of the Company's common stock outstanding immediately preceding the merger are
converted by virtue of the merger into other property, whether in the form of securities, cash, or otherwise; (c) a strategic corporate event, such as
a merger or acquisition, where the Company is technically the surviving entity, but where other elements of a change of control are present, i.e.,
change in management team or Board composition; (d) a transaction which the Board determines in its sole discretion to constitute a change in
control of the Company; or (e) any capital reorganization in which fifty percent (50%) of the Shares of the Company entitled to vote are
exchanged, then, the time during which Awards outstanding under the Plan become vested shall be accelerated and all outstanding Awards shall
become immediately exercisable upon such event and such Awards shall continue to be exercisable until the later of (i) twenty-four (24) months
from the effective date of such event, or (ii) the time specified in the Award Agreement during which the Award is exercisable following a
Participant's termination of service; provided, however, that in no event shall the Award be exercisable after the expiration of its term.

Article 19. Successors

All obligations of the Company under this Plan with respect to Awards granted hereunder shall be binding on any successor to the Company,
whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all
of the business and/or assets of the Company.

Article 20. General Provisions

20.1 Forfeiture Events.

(a) The Board may specify in an Award Agreement that the Participant's rights, payments, and benefits with respect to an Award shall be
subject to reduction, cancellation, forfeiture, or recoupment upon the occurrence of certain specified events, in addition to any otherwise
applicable vesting or performance conditions of an Award. Such events may include, but shall not be limited to, termination of employment for
cause, termination of the Participant's provision of services to the Company, Affiliate, and/or Subsidiary, violation of material Company, Affiliate,
and/or Subsidiary policies, breach of noncompetition, confidentiality, or other restrictive covenants that may apply to the Participant, or other
conduct by the Participant that is detrimental to the business or reputation of the Company, its Affiliates, and/or its Subsidiaries.

(b) If the Company is required to prepare an accounting restatement due to the material noncompliance of the Company, as a result of
misconduct, with any financial reporting

                                                    -20-

requirement under the securities laws, if the Participant knowingly or grossly negligently engaged in the
misconduct, or knowingly or grossly negligently failed to prevent the misconduct, or if the Participant is one of the individuals subject to automatic
forfeiture under Section 304 of the Sarbanes-Oxley Act of 2002, the Participant shall reimburse the Company the amount of any payment in
settlement of an Award earned or accrued during the twelve (12) month period following the first public issuance or filing with the United States
Securities and Exchange Commission (whichever just occurred) of the financial document embodying such financial reporting requirement.

20.2 Legend. The certificates for Shares may include any legend which the Board deems appropriate to reflect any restrictions on
transfer of such Shares.

20.3 Gender and Number. Except where otherwise indicated by the context, any masculine term used herein also shall include the
feminine, the plural shall include the singular, and the singular shall include the plural.

20.4 Severability. In the event any provision of this Plan shall be held illegal or invalid for any reason, the illegality or invalidity shall
not affect the remaining parts of this Plan, and this Plan shall be construed and enforced as if the illegal or invalid provision had not been
included.

20.5 Requirements of Law. The granting of Awards and the issuance of Shares under this Plan shall be subject to all applicable
laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.

20.6 Delivery of Title. The Company shall have no obligation to issue or deliver evidence of title for Shares issued under this Plan
prior to:

(a) Obtaining any approvals from governmental agencies that the Company determines are necessary or advisable; and

(b) Completion of any registration or other qualification of the Shares under any applicable national or foreign law or ruling of any
governmental body that the Company determines to be necessary or advisable.

20.7 Inability to Obtain Authority. The inability of the Company to obtain authority from any regulatory body having jurisdiction, which
authority is deemed by the Company's counsel to be necessary to the lawful issuance and sale of any Shares hereunder, shall relieve the
Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority shall not have been
obtained.

20.8 Investment Representations. The Board may require any individual receiving Shares pursuant to an Award under this Plan to
represent and warrant in writing that the individual is acquiring the Shares for investment and without any present intention to sell or distribute
such Shares.

20.9 Employees Based Outside of the United States. Notwithstanding any provision of

                                                    -21-

this Plan to the contrary, in order to comply
with the laws in other countries in which the Company, its Affiliates, and/or its Subsidiaries operate or have Employees, Directors, or Third Party
Service Providers, the Board, in its sole discretion, shall have the power and authority to:

(a) Determine which Affiliates and Subsidiaries shall be covered by this Plan;

(b) Determine which Employees and/or Directors or Third Party Service Providers outside the United States are eligible to participate in this
Plan;

(c) Modify the terms and conditions of any Award granted to Employees \and/or Directors or Third Party Service Providers outside the United
States to comply with applicable foreign laws;

(d) Establish subplans and modify exercise procedures and other terms and procedures, to the extent such actions may be necessary or
advisable. Any subplans and modifications to Plan terms and procedures established under this Section 20.9 by the Board shall be attached to
this Plan document as appendices; and

(e) Take any action, before or after an Award is made, that it deems advisable to obtain approval or comply with any necessary local
government regulatory exemptions or approvals.

Notwithstanding the above, the Board may not take any actions hereunder, and no Awards shall be granted, that would violate applicable
law.

20.10 Uncertificated Shares. To the extent that this Plan provides for issuance of certificates to reflect the transfer of Shares, the
transfer of such Shares may be effected on a noncertificated basis, to the extent not prohibited by applicable law or the rules of any stock
exchange.

20.11 Unfunded Plan. Participants shall have no right, title, or interest whatsoever in or to any investments that the Company, and/or
its Subsidiaries, and/or its Affiliates may make to aid it in meeting its obligations under this Plan. Nothing contained in this Plan, and no action
taken pursuant to its provisions, shall create or be construed to create a trust of any kind, or a fiduciary relationship between the Company and
any Participant, beneficiary, legal representative, or any other individual. To the extent that any person acquires a right to receive payments from
the Company, its Subsidiaries, and/or its Affiliates under this Plan, such right shall be no greater than the right of an unsecured general creditor of
the Company, a Subsidiary, or an Affiliate, as the case may be. All payments to be made hereunder shall be paid from the general funds of the
Company, a Subsidiary, or an Affiliate, as the case may be and no special or separate fund shall be established and no segregation of assets
shall be made to assure payment of such amounts except as expressly set forth in this Plan.

20.12 No Fractional Shares. No fractional Shares shall be issued or delivered pursuant to this Plan or any Award. The Board shall
determine whether cash, Awards, or other property shall be issued or paid in lieu of fractional Shares or whether such fractional Shares or any
rights thereto shall be forfeited or otherwise eliminated.

                                                    -22-

20.13 Retirement and Welfare Plans. Neither Awards made under this Plan nor Shares or cash paid pursuant to such Awards,
except pursuant to Covered Employee Annual Incentive Awards, may be included as "compensation" for purposes of computing the
benefits payable to any Participant under the Company's or any Subsidiary's or Affiliate's retirement plans (both qualified and non-qualified) or
welfare benefit plans unless such other plan expressly provides that such compensation shall be taken into account in computing a Participant's
benefit.

20.14 Deferred Compensation. No deferral of compensation (as defined under Code Section 409A or guidance thereto) is intended
under this Plan. Notwithstanding this intent, if any Award would be considered deferred compensation as defined under Code Section 409A and if
the Plan fails to meet the requirements of Code Section 409A with respect to such Award, then such Award shall be null and void. However, the
Board may permit deferrals of compensation pursuant to the terms of a Participant's Award Agreement, a separate plan or a subplan which
meets the requirements of Code Section 409A and any related guidance. Additionally, to the extent any Award is subject to Code Section 409A,
notwithstanding any provision herein to the contrary, the Plan does not permit the acceleration of the time or schedule of any distribution related
to such Award, except as permitted by Code Section 409A, the regulations thereunder, and/or the Secretary of the United States Treasury.

20.15 Nonexclusivity of this Plan. The adoption of this Plan shall not be construed as creating any limitations on the power of the
Board or Board to adopt such other compensation arrangements as it may deem desirable for any Participant.

20.16 No Constraint on Corporate Action. Nothing in this Plan shall be construed to: (i) limit, impair, or otherwise affect the
Company's or a Subsidiary's or an Affiliate's right or power to make adjustments, reclassifications, reorganizations, or changes of its capital or
business structure, or to merge or consolidate, or dissolve, liquidate, sell, or transfer all or any part of its business or assets; or, (ii) limit the right
or power of the Company or a Subsidiary or an Affiliate to take any action which such entity deems to be necessary or appropriate.

20.17 Governing Law. The Plan and each Award Agreement shall be governed by the laws of the State of Delaware, excluding any
conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Plan to the substantive law of another
jurisdiction. Unless otherwise provided in the Award Agreement, recipients of an Award under this Plan are deemed to submit to the exclusive
jurisdiction and venue of the federal or state courts of Delaware, to resolve any and all issues that may arise out of or relate to this Plan or any
related Award Agreement.

                                                    -23-10-K 2007 Exhibit 10.21

                                                                                    Exhibit 10.21

NPS PHARMACEUTICALS, INC.

SEPARATION AND RELEASE OF CLAIMS AGREEMENT

This Separation and Release of Claims Agreement ("Agreement") documents the agreement between
you, Gregory Torre, and NPS Pharmaceuticals, Inc., its subsidiaries and affiliates ("NPS") concerning the termination of
your status as an employee of NPS effective July 31, 2007.

RECITALS

	You have been employed by NPS.  Your employment is being terminated as part of the NPS March 2007
workforce reduction.  Your last day of employment is July 31, 2007.  

	You and NPS desire to resolve any and all disputes that may exist relating to your employment with NPS and the
termination of that employment relationship.

AGREEMENT

NOW, THEREFORE, in consideration of the mutual promises, covenants and agreements set forth herein, the
parties mutually agree as follows:

	Effective Date.  This Agreement is effective on the eighth (8th) day following your signing
this Agreement, provided that you do not revoke your execution of this Agreement as provided in Paragraph 16 below.  

	Severance Benefits.  In reliance on the releases and agreements set forth in this Agreement, NPS will
provide to you the following severance benefits upon the expiration of the revocation period described in Paragraph 16 below and the
unrevoked signing of this Agreement by you.

	You will receive 78 weeks of standard severance in the gross amount of $457,500 (Four Hundred Fifty-Seven
Thousand Five Hundred Dollars) from which normal payroll withholdings will be made. 

	Additionally you will receive the benefits to which you are entitled from the 2006 Executive Team Retention Plan
benefit (16,019 RSUs with the restriction lifted), available to you 30 days after your termination.

	NPS will pay for your COBRA coverage through the end of the month in which your standard severance ends.
Thereafter, you may continue COBRA coverage by paying the entire premium for the remaining period of your COBRA eligibility. 

	You have been given a letter describing your 401K Plan, Section 125 Cafeteria Plan, Personal Time Off
("PTO"), and, if applicable, Stock Purchase Plan benefits.  This letter also explains the effect of the termination of your employment
on the group life insurance policy on your life and your short-term and long term disability insurance.  You will receive the benefits described in
this subparagraph (d) regardless of whether you sign this Agreement.  

	Consideration Period.  You acknowledge that you have been given forty-five (45)days from receipt of this
Agreement, which includes NPS's ADEA Section 7(f)(1)(H) Disclosure Statement attached as Exhibit A, in which to consider and consult with
an attorney regarding this Agreement.  You acknowledge that you have had an adequate amount of time in which to consult with any person of
your choice about this Agreement prior to signing it.  

	Waiver of Consideration Period.  You may waive the 45-day consideration period by executing the
Waiver of 45-Day Period Under Separation and Release of Claims Agreement, which is attached as Exhibit B.  

	Release by Employee.  As a material inducement to NPS to enter into this Agreement and in
consideration for the payment of the amount set forth in this Agreement, you, for yourself and for all persons claiming by, through, or under
you, hereby absolutely, irrevocably, completely and unconditionally release and discharge NPS and each of NPS's subsidiaries, affiliates,
successors, assigns, agents, directors, officers, employees, representatives, attorneys and all persons acting by, through, under or in concert
with any of them ("Releasees") of and from any and all claims, demands, charges, grievances, damages, debts, liabilities,
accounts, costs, attorney's fees, expenses, liens, future rights, and causes of action of every kind and nature whatsoever based on or in any
way arising out of events or omissions occurring prior to the effective date of this Agreement ("Claims").  The Claims from which
you are releasing Releasees herein include, without limitation, breach of implied or express contract, breach of implied covenant of good faith
and fair dealing, libel, slander, wrongful discharge or termination, infliction of emotional distress, discrimination and any other claims under the
Age Discrimination in Employment Act, the Older Workers Benefit Protection Act, Title VII of the Civil Rights Act of 1964, the Fair Labor
Standards Act, the Americans With Disabilities Act, the Utah Antidiscrimination Act, the New Jersey Law Against Discrimination, the Worker
Adjustment and Retraining Notification Act (WARN Act), the Employee Retirement Income Security Act (ERISA), and all other laws prohibiting
age, race, religion, sex, sexual orientation, national origin, color, disability and other forms of discrimination, claims growing out of any legal
restrictions on NPS's right to terminate its employees, and all other claims arising in any way out of your employment relationship with NPS or
the termination of that relationship, whether now known or unknown, suspected or unsuspected, including future rights, based upon or in any
way arising out of events or omissions occurring prior to the effective date of this Agreement.  You specifically waive any and all claims for
back pay, front pay, or any other form of compensation, except as set forth herein.

You hereby waive any right to recover damages, costs, attorneys' fees, and any other relief in any proceeding or action
brought against NPS by any other party, including without limitation the Equal Employment Opportunity Commission, the Utah
Antidiscrimination and Labor Division, the New Jersey Division of Civil Rights, or other administrative agency asserting any claim, charge,
demand, grievance, or cause of action related to your employment relationship with NPS or the termination of that relationship.

You are not waiving your rights, if any, to unemployment insurance benefits or workers' compensation benefits.  You
further do not waive any rights you may have under the terms of NPS's pension or other NPS employee benefit plans.  You also do not waive any claims or rights

                                                    2

under the Age Discrimination in Employment Act which may arise from events occurring after the date of this
Agreement.

	Representations Regarding Claims.  You represent that you have not previously assigned or transferred,
or attempted to assign or transfer, to any third party, any of the Claims waived and released herein.  You represent that you have not filed any
claim, complaint, charge or lawsuit against NPS or any other Releasee with any governmental agency or any state or federal court, and agree
not to file any lawsuit at any time hereafter concerning your employment relationship with NPS or the termination of that relationship.

	Additional Consideration.  You acknowledge that the severance benefits provided to you pursuant to this
Agreement are in addition to any sums or payments to which you would be entitled without signing this Agreement.

	Confidential Information and Company Property.  You are reminded of the terms of the Non-Disclosure
and Non-Competition Agreement which you signed as part of the terms of your employment with NPS and which continues in effect after the
termination of your employment.  Under that agreement, you are required to protect and not disclose any information regarding NPS's
proprietary intellectual property, its financial condition, terms of its business relations, and all other Confidential Information as defined in that
agreement.  Anything you produced as an employee for NPS is the property of NPS.  You are obligated to leave with or return to NPS any
such documents whether tangible property or in electronic form belonging to NPS including, but not limited to, documents or tangible property
which may contain or reflect confidential information or trade secrets of NPS.  Such confidential information and trade secrets may include
scientific data, proprietary ideas, financial information, knowledge of specific business dealings or practices, employee information obtained
while performing your duties, or other matters which NPS attempts to maintain as confidential in the course of its business.  By signing this
Agreement, you certify that you have returned all property of NPS.

	Legal Fees.  NPS will be entitled to recover from you all reasonable legal fees and costs incurred in the
event that you file a lawsuit against NPS or any Releasee concerning any of the Claims released herein or otherwise breach this
Agreement.

	Entire Agreement.  This Agreement contains the entire agreement and understanding of NPS and you
concerning the subject matter hereof and this Agreement replaces all prior agreements, whether written or oral.  You acknowledge that NPS
has not made any representations whatsoever not contained in this Agreement to induce you to execute this Agreement and you are not
relying on any such representations in signing this Agreement.

	Governing Law.  This Agreement will be construed, enforced and governed in all respects by the laws of
the State of New Jersey and applicable federal law.  Any legal action regarding this Agreement may be initiated or maintained only in a state or
federal court in New Jersey.

	Provisions Severable.  The provisions of this Agreement are severable.  Should any provision of this
Agreement be void, voidable, or unenforceable under any applicable law, such provision will not affect or invalidate any other provision of this
Agreement.

                                                    3

	Employee Acknowledgement.  You acknowledge that you have read this Agreement carefully and fully
understand this Agreement.  You acknowledge that you have executed this Agreement voluntarily and that you are knowingly and voluntarily
releasing and waiving all Claims you may have against NPS.  You acknowledge that NPS has advised you to consult with an attorney of your
choice prior to signing this Agreement.

	Non-Disparagement.  You will not disparage or criticize, orally, in writing, by e-mail, on the Internet, or
through any other medium, NPS, its directors, officers, executives, management, employees, or operations to any third person or entity.

	Confidentiality.  You agree that you and your agents and representatives will keep this Agreement,
including its terms, strictly confidential, and you promise that you will not disclose, either directly or indirectly, any information concerning this
Agreement to anyone, except that:

	You may disclose this Agreement to your spouse or domestic partner and your legal, financial and tax advisors as
may be necessary for the rendition of professional services, each of whom must agree to be bound by the terms of this confidentiality
provision; and

	You may disclose this Agreement to the extent required by law, or in an action to enforce this Agreement or arising
from the breach of alleged breach of this Agreement.

	Revocation Period.  You have seven (7) days from the date on which you sign this Agreement to revoke
this Agreement by providing written notice (by fax, mail, or hand delivery) of your revocation to:

Glenn Melrose

Vice President, Human Resources

NPS Pharmaceuticals, Inc.

300 Interpace Parkway, Building B, 4th Floor 

Parsippany, New Jersey  07054

Fax:  973-658-8891

Your revocation, to be effective, must be received by the above-named person by the end of the seventh day after you
sign this Agreement.  This Agreement becomes effective on the eighth day after you sign this Agreement, providing that you have not revoked
this Agreement as provided above.

                                                    4

	
 

NPS PHARMACEUTICALS, INC.

___________________________________

                                Its: ________________________________

                               Date: ___________________________________
	
EMPLOYEE

________________________________

                                 Sign Name

	 	

Print Name _____________________________________

    Date: ______________________________

                                                    5

EXHIBIT A

ADEA SECTION 7(f)(1)(H) DISCLOSURE STATEMENT

In connection with NPS Pharmaceuticals, Inc.'s ("Company") March 2007 workforce
reduction program, you are being provided with information regarding (i) any class, unit or group of individuals covered by the program, and
any time limits applicable to the program and (ii) the job title and ages of all individuals selected for the program.  Selected employees are
employees of Company.  Only employees who are being terminated in the Company's March 2007 workforce reduction are selected for the
program.  Employees who have been selected for termination are being offered consideration for signing a Separation and Release of Claims
Agreement, a copy of which is being provided to you with this Disclosure Statement.  In order to be entitled to severance pay under the
program, you must sign and return the Separation and Release of Claims Agreement to Glenn Melrose, Vice President, Human Resources,
within forty-five (45) days after you receive it.  Once the signed Separation and Release of Claims Agreement is returned, you will have seven
(7)days within which to revoke it.

Attached is a listing of the job titles, selection factors, and ages of employees who were and were not selected for
termination and the offer of consideration for signing a Separation and Release of Claims Agreement.

	
Location 
	
Title
	
Age
	
DepartmentName
	
Type
	
Selection Factor

	
NJ
	
Drug Safety Systems Coord (P)
	
52
	
025 - Clnicl Drg Sfty/Phrm
	
Leaver
	
Job Eliminated

	
NJ
	
Sr. Contracts/Outsourcing Mgr.
	
53
	
045 - Contracts & Outsourcing
	
Leaver
	
# of posts reduced/emp. ranked lower

	
NJ
	
Director, Market Research
	
55
	
071 - Market Research
	
Leaver
	
Job Eliminated

	
NJ
	
Assoc. Director, Sys. Valid.
	
47
	
082 - Computer Resources
	
Leaver
	
Job Eliminated

	
NJ
	
Admin. Associate IV (P)
	
38
	
074 - Product Management
	
Leaver
	
Job Eliminated

	
NJ
	
System Architect, Sales & Mark
	
32
	
082 - Computer Resources
	
Leaver
	
Job Eliminated

	
NJ
	
Contracts and Outsourcing Spec
	
49
	
045 - Contracts & Outsourcing
	
Leaver
	
Job Eliminated

	
NJ
	
Manager, Financial Planning
	
34
	
080 - Accounting & Finance
	
Leaver
	
Job Eliminated

	
NJ
	
Receptionist II (P)
	
30
	
084 - Physical Facilities
	
Leaver
	
Job Eliminated

	
NJ
	
Project Management Coordinator
	
28
	
020 - Project Management
	
Leaver
	
Job Eliminated

	
NJ
	
Assoc. Director, Prof. Ed.
	
51
	
039 - Medical Communications
	
Leaver
	
Job Eliminated

	
NJ
	
Clinical Project Assistant
	
43
	
030 - Clinical Operations
	
Leaver
	
Job Eliminated

	
NJ
	
Sr. Market Research Analyst
	
29
	
071 - Market Research
	
Leaver
	
Job Eliminated

	
NJ
	
Manager, Regulatory Operations
	
60
	
053 - Regulatory Operations
	
Leaver
	
Job Eliminated

	
NJ
	
Sr. Clinical Research Sci. I
	
38
	
030 - Clinical Operations
	
Leaver
	
Job Eliminated

	
NJ
	
VP, Medical Affairs
	
44
	
035 - Medical Affairs
	
Leaver
	
Job Eliminated

	
NJ
	
Assoc. Director, Data Mgmt.
	
32
	
031 - Statistics Data Mgmt
	
Leaver
	
Job Eliminated

	
NJ
	
Assoc. Director, Statistics
	
39
	
031 - Statistics Data Mgmt
	
Leaver
	
Job Eliminated

	
NJ
	
Sr. Human Resources Generalist
	
32
	
070 - Human Resources
	
Leaver
	
Job Eliminated

	
NJ
	
Document/QC Specialist
	
47
	
027 - Medical Writing
	
Leaver
	
Job Eliminated

	
NJ
	
Director, Regulatory Affairs
	
52
	
032 - Regulatory Affairs
	
Leaver
	
Job Eliminated

	
NJ
	
Director, Info. Sys. Architect
	
50
	
082 - Computer Resources
	
Leaver
	
Job Eliminated

	
NJ
	
Coordinator, Prof. Ed.
	
37
	
035 - Medical Affairs
	
Leaver
	
Job Eliminated

	
NJ
	
Director, Data Management
	
45
	
031 - Statistics Data Mgmt
	
Leaver
	
Job Eliminated

	
NJ
	
Biometrics Specialist
	
32
	
031 - Statistics Data Mgmt
	
Leaver
	
Job Eliminated

	
NJ
	
Reg Operations Specialist
	
27
	
053 - Regulatory Operations
	
Leaver
	
Job Eliminated

	
NJ
	
Assoc. Director, Stats. Prog.
	
41
	
031 - Statistics Data Mgmt
	
Leaver
	
Job Eliminated

	
NJ
	
Supervisor, Office Services
	
46
	
084 - Physical Facilities
	
Leaver
	
Job Eliminated

	
NJ
	
Manager, Medical Writing
	
37
	
027 - Medical Writing
	
Leaver
	
Job Eliminated

	
NJ
	
Director, Biostatistics
	
53
	
031 - Statistics Data Mgmt
	
Leaver
	
Job Eliminated

	
NJ
	
Assoc. Director, Data Mgmt.
	
45
	
031 - Statistics Data Mgmt
	
Leaver
	
Job Eliminated

	
NJ
	
VP, Information Technology
	
46
	
082 - Computer Resources
	
Leaver
	
Job Eliminated

	
NJ
	
Assoc. Dir, Drug Safety & PVG
	
36
	
025 - Clnicl Drg Sfty/Phrm
	
Leaver
	
Job Eliminated

	
NJ
	
VP, Clinical Development
	
47
	
033 - Clinical Research
	
Leaver
	
Job Eliminated

	
NJ
	
Manager, GCP
	
30
	
036 - Quality Assurance
	
Leaver
	
Job Eliminated

	
NJ
	
Sr. Director, Drug Saf. & PVG
	
47
	
025 - Clnicl Drg Sfty/Phrm
	
Leaver
	
Job Eliminated

	
NJ
	
Assoc. Director, Program Mgmt.
	
42
	
020 - Project Management
	
Leaver
	
Job Eliminated

	
NJ
	
Medical Director, GI
	
45
	
033 - Clinical Research
	
Leaver
	
Job Eliminated

	
NJ
	
Sr. Manager, Regulatory Ops
	
47
	
053 - Regulatory Operations
	
Leaver
	
Job Eliminated

	
NJ
	
Helpdesk Technician (P)
	
36
	
082 - Computer Resources
	
Leaver
	
Job Eliminated

	
NJ
	
Clinical Research Scientist II
	
49
	
030 - Clinical Operations
	
Leaver
	
Job Eliminated

	
NJ
	
Director, Fin, Plan and Analay
	
39
	
080 - Accounting & Finance
	
Stay
	
 

	
NJ
	
Director, Human Resources
	
34
	
070 - Human Resources
	
Stay
	
 

	
NJ
	
Director, Regulatory Liaison
	
44
	
032 - Regulatory Affairs
	
Stay
	
 

	
NJ
	
Executive Assistant (P)
	
47
	
032 - Regulatory Affairs
	
Stay
	
 

	
NJ
	
Executive Assistant
	
39
	
029 - Med and Commercial Adm
	
Stay
	
 

	
NJ
	
Sr. Contracts/Outsourcing Mgr.
	
32
	
045 - Contracts & Outsourcing
	
Stay
	
 

	
NJ
	
Business Development Spec.
	
50
	
061 - Corporate Development
	
Stay
	
 

	
NJ
	
Director, Contracts and Outsou
	
52
	
045 - Contracts & Outsourcing
	
Stay
	
 

	
NJ
	
Assoc. Director, Resource Mgmt
	
34
	
030 - Clinical Operations
	
Stay
	
 

	
NJ
	
Sr. Director Regulatory Ops
	
47
	
053 - Regulatory Operations
	
Stay
	
 

	
NJ
	
Sr. Director, Medical Affairs
	
58
	
035 - Medical Affairs
	
Stay
	
 

	
NJ
	
Executive Assistant (CEO)
	
53
	
090 - CEO
	
Stay
	
 

	
NJ
	
VP, Commericial Operations
	
50
	
074 - Product Management
	
Stay
	
 

	
NJ
	
Executive Assistant
	
52
	
060 - Business Development
	
Stay
	
 

	
NJ
	
Director, Clinical Operations
	
51
	
030 - Clinical Operations
	
Stay
	
 

	
NJ
	
VP, Alliance Management
	
49
	
061 - Corporate Development
	
Stay
	
 

	
SL
	
Director, Corporate Strategy
	
35
	
060 - Business Development
	
Leaver
	
Job Eliminated

	
SL
	
Research Associate II
	
31
	
007 - Screening
	
Leaver
	
Job Eliminated

	
SL
	
Research Associate I
	
28
	
013 - Tissue Culture
	
Leaver
	
Job Eliminated

	
SL
	
Research Associate III
	
41
	
028 - Drug Metabolism (DMPK)
	
Leaver
	
Job Eliminated

	
SL
	
Scientist I
	
31
	
028 - Drug Metabolism (DMPK)
	
Leaver
	
Job Eliminated

	
SL
	
Research Associate II
	
25
	
013 - Tissue Culture
	
Leaver
	
Job Eliminated

	
SL
	
Research Info. Spec. II (S)
	
45
	
083 - Library
	
Leaver
	
Job Eliminated

	
SL
	
Scientist III
	
47
	
001 - SLC Biology
	
Leaver
	
Job Eliminated

	
SL
	
Paralegal, Intellectual Prop.
	
39
	
052 - Patents
	
Leaver
	
Job Eliminated

	
SL
	
Scientist III
	
47
	
028 - Drug Metabolism (DMPK)
	
Leaver
	
Job Eliminated

	
SL
	
Research Associate II
	
27
	
013 - Tissue Culture
	
Leaver
	
Job Eliminated

	
SL
	
Research Associate III
	
51
	
028 - Drug Metabolism (DMPK)
	
Leaver
	
Job Eliminated

	
SL
	
Research Associate II
	
29
	
028 - Drug Metabolism (DMPK)
	
Leaver
	
Job Eliminated

	
SL
	
Facility Manager
	
59
	
084 - Physical Facilities
	
Leaver
	
Job Eliminated

	
SL
	
Discovery Research Analyst
	
35
	
082 - Computer Resources
	
Leaver
	
Job Eliminated

	
SL
	
Research Associate II
	
32
	
028 - Drug Metabolism (DMPK)
	
Leaver
	
Job Eliminated

	
SL
	
Manager, In Vivo Core Group
	
52
	
001 - SLC Biology
	
Leaver
	
Job Eliminated

	
SL
	
Manager, Animal Facilities
	
48
	
001 - SLC Biology
	
Leaver
	
Job Eliminated

	
SL
	
VP, Corp. Law & Assoc. GC
	
46
	
050 - Legal
	
Leaver
	
Job Eliminated

	
SL
	
Manager, Res Inf Services (S)
	
37
	
083 - Library
	
Leaver
	
Job Eliminated

	
SL
	
Admin. Associate IV (S)
	
38
	
050 - Legal
	
Leaver
	
Job Eliminated

	
SL
	
Intellectual Property Counsel
	
32
	
052 - Patents
	
Leaver
	
Job Eliminated

	
SL
	
Records Specialist
	
51
	
030 - Clinical Operations
	
Leaver
	
Job Eliminated

	
SL
	
Scientist V
	
56
	
001 - SLC Biology
	
Leaver
	
Job Eliminated

	
SL
	
Receptionist (S)
	
37
	
084 - Physical Facilities
	
Leaver
	
Job Eliminated

	
SL
	
Scientist I
	
48
	
001 - SLC Biology
	
Leaver
	
Job Eliminated

	
SL
	
Corporate Safety Manager
	
40
	
084 - Physical Facilities
	
Leaver
	
Job Eliminated

	
SL
	
Network Systems Administrator
	
57
	
082 - Computer Resources
	
Leaver
	
Job Eliminated

	
SL
	
Helpdesk Technician
	
23
	
082 - Computer Resources
	
Leaver
	
Job Eliminated

	
SL
	
IT Support Specialist (S)
	
33
	
082 - Computer Resources
	
Leaver
	
Job Eliminated

	
SL
	
Investor Relations Specialist
	
54
	
062 - Investor Relations
	
Leaver
	
Job Eliminated

                                                    7

	
SL
	
HR Associate
	
35
	
070 - Human Resources
	
Leaver
	
Job Eliminated

	
SL
	
Laboratory Glass Washer (Lab)
	
50
	
084 - Physical Facilities
	
Leaver
	
Job Eliminated

	
SL
	
Research Associate IV
	
33
	
028 - Drug Metabolism (DMPK)
	
Leaver
	
Job Eliminated

	
SL
	
Research Associate IV
	
31
	
028 - Drug Metabolism (DMPK)
	
Leaver
	
Job Eliminated

	
SL
	
Scientist III
	
44
	
028 - Drug Metabolism (DMPK)
	
Leaver
	
Job Eliminated

	
SL
	
Executive Assistant
	
41
	
010 - Research Administration
	
Leaver
	
Job Eliminated

	
SL
	
Hardware Support Technician
	
32
	
082 - Computer Resources
	
Leaver
	
Job Eliminated

	
SL
	
Scientist IV
	
45
	
001 - SLC Biology
	
Leaver
	
Job Eliminated

	
SL
	
Research Associate IV
	
36
	
007 - Screening
	
Leaver
	
Job Eliminated

	
SL
	
Sr. Manager, Tissue Culture
	
44
	
013 - Tissue Culture
	
Leaver
	
Job Eliminated

	
SL
	
Research Associate I
	
23
	
007 - Screening
	
Leaver
	
Job Eliminated

	
SL
	
Scientist II
	
51
	
003 - TOR Chemistry
	
Leaver
	
Job Eliminated

	
SL
	
Sr. Director, Corp. Strategy
	
36
	
060 - Business Development
	
Leaver
	
Job Eliminated

	
SL
	
Admin. Associate III (S)
	
26
	
084 - Physical Facilities
	
Leaver
	
Job Eliminated

	
SL
	
Sr. Systems Administrator
	
38
	
082 - Computer Resources
	
Leaver
	
Job Eliminated

	
SL
	
Systems Analyst (S)
	
35
	
082 - Computer Resources
	
Leaver
	
Job Eliminated

	
SL
	
Sr. Systems Architect
	
39
	
082 - Computer Resources
	
Leaver
	
Job Eliminated

	
SL
	
Admin. Associate IV (S)
	
36
	
080 - Accounting & Finance
	
Leaver
	
Job Eliminated

	
SL
	
Payroll Specialist
	
35
	
080 - Accounting & Finance
	
Leaver
	
Job Eliminated

	
SL
	
Accounts Payable Specialist
	
60
	
080 - Accounting & Finance
	
Leaver
	
Job Eliminated

	
SL
	
Manager, Accounts Payable
	
36
	
080 - Accounting & Finance
	
Leaver
	
Job Eliminated

	
SL
	
Sr. Accountant, Comp/Fin. Anl.
	
37
	
080 - Accounting & Finance
	
Leaver
	
Job Eliminated

	
SL
	
Scientist I
	
35
	
028 - Drug Metabolism (DMPK)
	
Leaver
	
Job Eliminated

	
SL
	
Human Resources Generalist II
	
28
	
070 - Human Resources
	
Leaver
	
Job Eliminated

	
SL
	
Assistant Controller
	
42
	
080 - Accounting & Finance
	
Leaver
	
Job Eliminated

	
SL
	
Paralegal, Corp. & Securities
	
40
	
050 - Legal
	
Leaver
	
Job Eliminated

	
SL
	
Corporate Counsel
	
31
	
050 - Legal
	
Leaver
	
Job Eliminated

	
SL
	
Chief Patent Counsel
	
44
	
052 - Patents
	
Leaver
	
Job Eliminated

	
SL
	
Admin. Associate III (S)
	
26
	
052 - Patents
	
Leaver
	
Job Eliminated

	
SL
	
Sr. Facilities Technician
	
36
	
084 - Physical Facilities
	
Leaver
	
Job Eliminated

	
SL
	
Sr. Director, Admin. Services
	
46
	
084 - Physical Facilities
	
Leaver
	
Job Eliminated

	
SL
	
Sr. Network and Sec. Arch II
	
37
	
082 - Computer Resources
	
Leaver
	
Job Eliminated

	
SL
	
Corporate Controller
	
39
	
080 - Accounting & Finance
	
Leaver
	
Job Eliminated

	
SL
	
Document Management Specialist
	
27
	
026 - Preclinical Safety
	
Leaver
	
Job Eliminated

	
SL
	
Records Management Specialist
	
45
	
030 - Clinical Operations
	
Leaver
	
Job Eliminated

	
SL
	
Sr. Director, Safety Assess.
	
51
	
028 - Drug Metabolism (DMPK)
	
Leaver
	
Job Eliminated

	
SL
	
Sr. Director, Pre-Clinical SA
	
47
	
026 - Preclinical Safety
	
Leaver
	
Job Eliminated

	
SL
	
Sr. Clinical Pharmacokineticis
	
33
	
028 - Drug Metabolism (DMPK)
	
Leaver
	
Job Eliminated

	
SL
	
Scientist V
	
48
	
001 - SLC Biology
	
Stay
	
 

                                                    8

WAIVER OF 45-DAY PERIOD UNDER SEPARATION and release of claims AGREEMENT

This Waiver of 45-Day Period Under Separation and Release of Claims Agreement ("Wiaver") is
executed by Gregory Torre on this _____ date of _______, 2007.

RECITALS

 1.You have received the Separation and Release of Claims Agreement ("Agreement") with
NPS Pharmaceuticals, Inc. ("NPS" or "the Company"), which will be effective July 31, 2007.

2.Your status as an employee of the Company will be terminated as part of the NPS March 2007 workforce
reduction.  You last day of employment is July 31, 2007  

3.Under the Agreement, you will receive certain severance benefits which you would not otherwise be entitled to
receive from NPS.

4.In consideration of receipt of such severance benefits, you will release all of your claims against the Company in
connection with your employment relationship with NPS and the termination of that relationship pursuant to Paragraph 5 of the Agreement,
including any claims under the Age Discrimination in Employment Act and the Older Workers' Benefit Protection Act.

5.Pursuant to Paragraph 3 of the Agreement, you have been given forty-five (45) days from receipt of the
Agreement in which to consider and consult with an attorney regarding the Agreement.  

6.You desire to waive this forty-five (45) day period.

WAIVER

Based on the foregoing Recitals, and on the mutual covenants contained herein, you agree as follows:

1.Effective Date of Waiver.  This Waiver is effective on the date that it is executed by you.

2.Revocation Period.  You may revoke this Waiver within seven (7) days of execution of this Waiver.
This Waiver shall become effective on the eighth (8TH) day following your signing of the Waiver.  

3.Exercise of Right of Revocation.  To revoke this Waiver, you must provide written notice (by fax, mail,
or hand delivery) of your revocation to:

                                                    9

Glenn Melrose

Vice President, Human Resources

NPS Pharmaceuticals, Inc.

300 Interpace Parkway, Building B, 4th Floor 

Parsippany, New Jersey  07054

Fax:  973-658-8891

Your revocation, to be effective, must be received by Glenn Melrose by the end of the seventh (7th) day
after you sign this Waiver.  

	
EMPLOYEE

________________________________

	
Name: Gregory Torre

Date: ___________________________

	 

                                                    10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}]]